Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir

doi:10.5500/wjt.v15.i2.102671

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (17)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-5)

Sum=15

Jun 18, 2025 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Transplant. Jun 18, 2025; 15(2): 102671
Published online Jun 18, 2025. doi: 10.5500/wjt.v15.i2.102671

Table 1 Patient baseline characteristics

Characteristics	n = 15398
Age (years), mean (SD)	52.39 (13.18)
Age category, n (%)
18 to < 45	4395 (28.54)
45 to < 65	8111 (52.68)
65 to < 75	2670 (17.34)
≥ 75	222 (1.44)
Sex, n (%)
Male	9039 (58.70)
Female	6359 (41.30)
Region¹, n (%)
South	7890 (51.24)
Northeast	4324 (28.08)
Midwest	1951 (12.67)
West	1233 (8.01)
Induction immunosuppressive therapy, n (%)
Thymoglobulin/anti-thymocyte globulin	5570 (36.17)
Basiliximab	2236 (14.52)
Alemtuzumab	1524 (9.90)
Rituximab	143 (0.93)
Initial maintenance immunosuppressive therapy, n (%)
Calcineurin inhibitors	15292 (99.31)
Tacrolimus	15250 (99.04)
Cyclosporine non-modified	451 (2.93)
Cyclosporine modified	0 (0.00)
Mycophenolic acid	12675 (82.32)
Azathioprine	330 (2.14)
Sirolimus	165 (1.07)
Everolimus	133 (0.86)
Corticosteroid therapy within 3 months post kidney transplantation, n (%)	14156 (91.93)
Prednisone	14048 (91.23)
Methyl prednisone	2927 (19.01)
Prednisolone	237 (1.54)
Calendar year of transplant, n (%)
2012	780 (5.07)
2013	1063 (6.90)
2014	1158 (7.52)
2015	1564 (10.16)
2016	1791 (11.63)
2017	2087 (13.55)
2018	2378 (15.44)
2019	2638 (17.13)
2020	1933 (12.55)
2021	6 (0.04)
Modified CCI², mean (SD)	1.22 (1.97)
Modified CCI category, n (%)
0	8064 (52.37)
1-2	4669 (30.32)
3-4	1661 (10.79)
≥ 5	1004 (6.52)
CCI comorbidity, n (%)
Chronic diabetes	4118 (26.74)
Congestive heart failure	1951 (12.67)
Peripheral vascular disease	1974 (12.82)
Chronic pulmonary disease	1351 (8.77)
Mild to moderate diabetes	1112 (7.22)
Mild liver disease	1006 (6.53)
Cerebrovascular disease	1000 (6.49)
Myocardial infarction	732 (4.75)
Cancer	704 (4.57)
Rheumatologic disease	623 (4.05)
Moderate liver disease	516 (3.35)
Metastatic solid tumor	308 (2.00)
AIDS	298 (1.94)
Peptic ulcer disease	205 (1.33)
Hemiplegia	79 (0.51)
Dementia	27 (0.18)

¹Region was categorized based on United States Census Bureau.

²Charlson Comorbidity Index (CCI) was calculated based on a modification of the method described in Quan et al[28] (2005).The Quan method was modified to omit renal disease from the calculation of CCI and from the list of comorbid conditions included.

AIDS: Acquired immunodeficiency syndrome; CCI: Charlson Comorbidity Index.

Citation: Beyer AP, Moise PA, Wong M, Gao W, Xiang C, Shen P, Pavlakis M, Vincenti F, Wang W. Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir. World J Transplant 2025; 15(2): 102671
URL: https://www.wjgnet.com/2220-3230/full/v15/i2/102671.htm
DOI: https://dx.doi.org/10.5500/wjt.v15.i2.102671